EN
中文 EN
Located in California-US and Guangzhou-China, Burning Rock provides global support for drug clinical trials
US CLIA/CAP Lab:
121 Innovation Drive, Irvine, California, USA
CLIA
CAP
CHINA CLIA/CAP Lab:
No.5,North Xingdao Ring Road,International Biological Island,Guangzhou,China
CLIA
CAP
NCCL
NMPA
ISO15189
ISO13485
Multi-dimensional Pipeline: Empowering Your Drug Development
Solid Tumor Testing
Tissue Testing
OncoScreen® plus
520-gene pane
Oncoscreen® Focus
9-gene panel
OncoScreen Focus® CDx Tissue Kit
13-gene panel
Liquid Biopsy
OncoCompass® plus
520-gene panel
OncoCompass® Target
168-gene panel
Hematologic Malignancies Testing
Blood Neoplasms
OncoScreen® HEME
The dual-omics detection technology of DNA (569 Gene) and RNA (322 Gene)
RUO/IUO
Technology for Multi-omics Detection
OncoScreen® WES
Whole exome sequencing
OncoScreen® cap-WTS
Exome Capture-based RNA-seq
OncoScreen® WGS
Whole genome sequencing
MRD
MRD Dynamic ctDNA Monitoring
Wide Application of NGS Tests in Clinical & Post-Marketing Study
NCT04305496 (Phase III)
Burning Rock's flagship comprehensive genomic profiling (CGP) product, OncoScreen Plus, are used to determine the activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients enrolled in China.
NEJM 2023
NCT03486678 (Phase II)
Burning Rock’s OncoScreen® Plus was employed to assess the correlation between bTMB and ctDNA, which showed a positive prognosis.
JIMC 2020
Case Reports: The first clinical testing of EGFR T790M/C797S mutation for guiding treatment in China
BNR OncoScreen® Plus, OncoCompass® Target and LungCure® CDx panel were used.
J Thorac Oncol 2020
NCT02274337 (Phase I)
OncoCompass® Target decoding the mechanisms of acquired resistance against EGFR-TKI AC0010.
JTO 2018
NCT02282267 (Phase II)
BENEFIT Study, cooperated with AstraZenaca, BNR OncoCompass® Target revealed the diverse effects drive by EGFR co-mutation on the benefit of Gefitinib in NSCLC.
Lancet Respiratory Medicine 2018
Mature QMS and Operation System Accelerate Your Clinical Trials
We Could Offer More

Genomic Data Solutions

Clinical Trial Solutions

CDx Development & Commercialization

Precision Patient Recruitment
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."